Abstract: ObjectiveTo evaluate clinical efficacy and safety of different doses of interferon（IFN）alfa-2b in the management of patients with chronic hepatitis C. Methods 61 patients with chronic hepatitis C were randomly divided into three groups,who received 48 week treatment and 24 week follow up with IFN alfa-2b（5MU）+ribavarin,IFN alfa-2b（3MU）+ribavarin,ribavarin alone,respectively. Results After 48 week treatment,ETVR were 68.2% and 61.9% respectively in the groups with IFN alfa-2b（5MU）+ribavarin and IFN alfa-2b（3MU）+ribavarin,which were significantly higher than that in the group with ribavarin（5.6%,P<0.01）;After 24 week follow up,SVR were 50.0% and 42.9% respectively in the groups with IFN alfa-2b（5MU）+ribavarin and IFN alfa-2b（3MU）+ribavarin,which were significantly higher than that in the group with ribavarin（0%,P<0.01）;There was no difference between two groups with different doses of IFN alfa-2b in the change of liver fibrosis indexes and side-effects. Conclusion ETVR and SVR of different doses of IFN alfa-2b were satisfactory at the end of treatment,while the effect of 5MU group was better than the group of 3MU. Both of two groups were able to reduce liver fibrosis indexes and improve hepatic histology.

Key words: Chronic hepatitis C, Interferon α-2b, Dose, Efficacy